SGLT2抑制剂达格列净增加2型糖尿病患者骨骼肌与脑脂肪酸摄取:一项随机双盲安慰剂对照正电子发射断层扫描研究
该6周随机双盲安慰剂对照试验纳入53例接受二甲双胍治疗的2型糖尿病患者,每日接受10 mg达格列净或安慰剂,用PET定量组织脂肪酸摄取。38例完成研究,达格列净组骨骼肌和全脑脂肪酸摄取较安慰剂组显著增加,小肠及内脏、皮下脂肪组织摄取无显著变化。
要点
- 达格列净组骨骼肌脂肪酸摄取较安慰剂组增加1.0 [0.07, 2.0] μmol·100 g⁻¹·min⁻¹(P=0.032)。
- 达格列净组全脑脂肪酸摄取较安慰剂组增加0.10 [0.02, 0.17] μmol·100 g⁻¹·min⁻¹(P=0.01),灰质和白质均可见。
- 小肠及内脏、皮下脂肪组织脂肪酸摄取无显著变化。
核心结论
- 6周达格列净治疗增加骨骼肌和脑脂肪酸摄取,部分由游离脂肪酸可用性升高驱动,该结果与既往间接测量显示的SGLT2抑制增强脂肪酸代谢一致,并将脂肪酸利用增加的观念扩展至肌肉和脑。
研究设计与样本
- 6周随机双盲安慰剂对照试验,53例接受二甲双胍治疗的2型糖尿病患者每日接受10 mg达格列净或安慰剂。
- 用PET和长链脂肪酸类似物放射性示踪剂14(R,S)-[18F]氟-6-硫代十七烷酸在基线和治疗结束时定量组织脂肪酸摄取。
- 采用ANCOVA评估治疗效应,结果以组间差异的最小二乘均数和95%CI报告。
主要发现
- 共38例患者完成研究(达格列净组n=21,安慰剂组n=17)。
- 6周后达格列净组骨骼肌脂肪酸摄取较安慰剂组增加1.0 [0.07, 2.0] μmol·100 g⁻¹·min⁻¹(P=0.032)。
- 达格列净组全脑脂肪酸摄取较安慰剂组增加0.10 [0.02, 0.17] μmol·100 g⁻¹·min⁻¹(P=0.01),灰质和白质区域均观察到该效应。
- 小肠、内脏脂肪组织和皮下脂肪组织脂肪酸摄取无显著变化。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The aim of this study was to investigate the impact of the sodium-glucose cotransporter 2 (SGLT2) inhibitor dapagliflozin on tissue fatty acid (FA) uptake in the skeletal muscle, brain, small intestine, and subcutaneous and visceral adipose tissue of individuals with type 2 diabetes by using positron emission tomography (PET). RESEARCH DESIGN AND METHODS: In a 6-week randomized double-blind placebo-controlled trial, 53 patients with type 2 diabetes treated with metformin received either 10 mg dapagliflozin or placebo daily. Tissue FA uptake was quantified at baseline and end of treatment with PET and the long-chain FA analog radiotracer 14(R,S)-[18F]fluoro-6-thia-heptadecanoic acid. Treatment effects were assessed using ANCOVA, and the results are reported as least square means and 95% CIs for the difference between groups. RESULTS: A total of 38 patients (dapagliflozin n = 21; placebo n = 17) completed the study. After 6 weeks, skeletal muscle FA uptake was increased by dapagliflozin compared with placebo (1.0 [0.07, 2.0] μmol ⋅ 100 g-1 ⋅ min-1; P = 0.032), whereas uptake was not significantly changed in the small intestine or visceral or subcutaneous adipose tissue. Dapagliflozin treatment significantly increased whole-brain FA uptake (0.10 [0.02, 0.17] μmol ⋅ 100 g-1 ⋅ min-1; P = 0.01), an effect observed in both gray and white matter regions. CONCLUSIONS: Six weeks of treatment with dapagliflozin increases skeletal muscle and brain FA uptake, partly driven by a rise in free FA availability. This finding is in accordance with previous indirect measurements showing enhanced FA metabolism in response to SGLT2 inhibition and extends the notion of a shift toward increased FA use to muscle and brain.
引用
- Latva-Rasku A, Rebelos E, Tuisku J, et al. SGLT2 Inhibitor Dapagliflozin Increases Skeletal Muscle and Brain Fatty Acid Uptake in Individuals With Type 2 Diabetes: A Randomized Double-Blind Placebo-Controlled Positron Emission Tomography Study. Diabetes Care. 2024. PMID: 38941156. doi:10.2337/dc24-0470
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。